07:51 AM EDT, 04/10/2024 (MT Newswires) -- Spectral Medical Inc. ( EDTXF ) , advancing therapeutic options for sepsis and septic shock, on Wednesday released an update on the Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

The company reports that 101 patients enrolled to-date, with a record 17 patients enrolled in Q1 2024 alone. So far, 20 patients have enrolled in 2024, the most robust enrollment rate since the start of the Tigris study, Spectral said.

Spectral confirms that 49 patients are required to full enrollment, and the company is entering the final push to fully enroll and finish the Tigris trial.

There are currently 22 Tigris trial sites, with an additional two new, high quality clinical sites, to come on board.